Humanized 3F8 Anti-G(D2) Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial

IMPORTANCE: Chimeric and murine anti-G(D2) antibodies are active against neuroblastoma, but the development of neutralizing antibodies can compromise efficacy. To decrease immunogenicity, hu3F8, a humanized anti-G(D2) antibody, was constructed. OBJECTIVE: To find the maximum-tolerated dose of hu3F8...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Kushner, Brian H., Cheung, Irene Y., Modak, Shakeel, Basu, Ellen M., Roberts, Stephen S., Cheung, Nai-Kong
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2018
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440722/
https://ncbi.nlm.nih.gov/pubmed/30326045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares